GENE ONLINE|News &
Opinion
Blog

2022-10-11| Trials & Approvals

Action Date Set for Gilead Sciences’ HR+/HER2- breast cancer sBLA

by Max Heirich
Share To

The United States Food and Drug Administration (FDA) accepted Gilead Sciences’ supplemental Biologics License Application (sBLA) for Trodelvy (sacituzumab govitecan-hziy) for priority review. With approvals in over thirty-five countries, this sBLA expands the breast cancer treatment’s use for unresectable locally advanced or metastatic hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative. 

The basis of the sBLA is the Phase 3 TROPiCS-02 study, which saw a significant reduction in the risk of disease progression or death.

Related Article: Roche’s Newly Approved Companion Diagnostic May Open Treatment Options for HER2-low Patients

The Expanded Use of Trodelvy

Trodelvy is a Trop-2-directed antibody and topoisomerase inhibitor conjugate for the treatment of various forms of cancer. Originally, the drug won approval for treating previously-treated metastatic triple-negative breast cancer (TNBC) in April 2020. A year later, the FDA granted Trodelvy approval as a first treatment for TNBC, with approval for use as a urothelial cancer (UC) treatment coming just days later. 

Earlier this year, Gilead announced topline results from the TROPiCS-02 study, which compared Trodelvy to other chemotherapies in treating HR+/HER2- breast cancer. Though HER2- cancer lacks the levels of the protein used for targeted therapies, emerging drugs instead target the HER2 receptors. Another example of this is AstraZeneca and Merck’s LYNPARZA® (olaparib). The other therapies viewed in the study included eribulin, capecitabine, gemcitabine, and vinorelbine. 

Published in the Journal of Clinical Oncology, TROPiCS-02 demonstrated a 34% reduction in risk of disease progression or death along with a consistent safety profile with prior studies. 

With the results from TROPiCS-02, Gilead submitted an sBLA for Trodelvy’s expanded use for HR+/HER2- breast cancer. After a few months, the FDA accepted the sBLA, granting it priority review.

On the acceptance, Bill Grossman, MD, PhD, Senior Vice President and Therapeutic Area Head at Gilead Oncology, said, “People with pre-treated HR+/HER2- metastatic breast cancer who have progressed on endocrine-based therapies and chemotherapy have limited treatment options, and we look forward to working with the FDA to potentially make Trodelvy available to patients who need it most.”

Currently, Trodelvy has no approval for HR+/HER2- metastatic breast cancer from any regulatory agency. However, the target action date for a decision on the sBLA is set for February 2023. Potentially, that is the date when Trodelvy gains yet another approval. 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Fake Ozempic Floods Market as FDA Warns Patients to Check Authenticity of Prescriptions
2025-04-16
Breaking New Ground in 2025 with 8 First-in-Class Drugs Close to FDA Approval – Part II
2025-04-01
Breaking New Ground in 2025 with 8 First-in-Class Drugs Close to FDA Approval – Part I
2025-03-31
LATEST
Exosomes: What They Do and Who’s Doing What
2025-04-21
Eli Lilly’s Orforglipron Shows Phase 3 Success: First Oral GLP-1 Drug for Type 2 Diabetes and Weight Loss
2025-04-21
Dupixent Makes History with FDA Approval as First New CSU Treatment in Over a Decade
2025-04-20
Multiple PCV Doses May Be Needed for Immunocompromised Type 2 Diabetics to Maintain Protection, Study Finds
2025-04-19
Multiple PCV Doses May Be Needed for Immunocompromised Individuals with Type 2 Diabetes
2025-04-19
Dr. Lauren Krupp, FAAN, Advocates Early Intervention and Family Support in Pediatric MS Treatment.
2025-04-19
Dr. Lauren B. Krupp Recommends Early, Aggressive Treatment with High-Efficacy Therapies for Pediatric Multiple Sclerosis
2025-04-19
EVENT
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
2025-04-26
SABPA OC/LA 17th Annual Biomedical Forum
Irvine, California, United States
2025-05-03
29th Taiwan Joint Cancer Conference 2025
Taipei, Taiwan
2025-05-05
Swiss Biotech Day 2025
Basel, Switzerland
Scroll to Top